Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Go back to Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
(AMEX: IDXG) Delayed: 1.45 --0 (-0%)
Previous Close $1.45    52 Week High $0.64 
Open $1.45    52 Week Low $0.10 
Day High $1.45    P/E N/A 
Day Low $1.45    EPS $0.00 
Volume 23,402       

(NASDAQ: VYNT) Delayed: 0.26 --0 (-0%)
Previous Close $0.26    52 Week High
Open $0.89    52 Week Low
Day High $0.26    P/E N/A 
Day Low $0.26    EPS
Volume 44,809